Prognostic factors for survival in metastatic renal cell carcinoma patients with brain metastases receiving targeted therapy
Date
2018Author
YILDIZ, İbrahim
Surmeli, Zeki
Turhal, Nazim Serdar
Bavbek, Sevil
Koca, Dogan
Tural, Deniz
Basaran, Mert
Bilici, Ahmet
Selcukbiricik, Fatih
Ozer, Leyla
Karadurmus, Nuri
Kaplan, Mehmet A.
Akman, Tulay
Bayoglu, Ibrahim
UYSAL, MÜKREMİN
Yildiz, Yasar
TANRIVERDİ, ÖZGÜR
Yazici, Ozan
Metadata
Show full item recordAbstract
Background: The primary objective of our study was to examine the clinical outcomes and prognosis of patients with metastatic renal cell carcinoma (mRCC) with brain metastases (BMs) receiving targeted therapy. Patients and methods: Fifty-eight patients from 16 oncology centers for whom complete clinical data were available were retrospectively reviewed. Results: The median age was 57 years (range 30-80). Most patients underwent a nephrectomy (n = 41; 70.7%), were male (n = 42; 72.4%) and had clear-cell (CC) RCC (n = 51; 87.9%). Patients were treated with first-line suni-tinib (n = 45; 77.6%) or pazopanib (n = 13; 22.4%). The median time from the initial RCC diagnosis to the diagnosis of BMs was 9 months. The median time from the first occurrence of metastasis to the development of BMs was 7 months. The median overall survival (OS) of mRCC patients with BMs was 13 months. Time from the initial diagnosis of systemic metastasis to the development of BMs (2; p2) were independent risk factors for a poor prognosis.
Collections
- Makale [92796]